ALSO NOTED: Most patients don't respond to breast cancer drug; Germans investigating Bayer for aspirin price-fixing;

> Most women with breast cancer don't respond to the common chemo drug Taxol, according to a new study from the University of Texas M.D. Anderson Cancer Center--but the 15 percent to 20 percent who have overactive HER-2 genes do, raising hopes of personalizing chemotherapy. Report

> German antitrust regulators searched the offices of Bayer for evidence that the drug maker has engaged in aspirin price-fixing. Report

> The FDA warned Medtronic against marketing its spinal treatment systems more broadly than their approved uses would allow. Report

> Pfizer is likely to get $6.7 million in tax breaks for a $50 million construction project near St. Louis. Report

> Glenmark Pharmaceuticals of India plans to raise $150 million on the financial markets, including a stock offering. Report

> The Street's Lenny Dykstra is bullish on Wyeth stock. Report

> Glaxo has agreed to pay Synta $80 million up front and up to $1.1 billion in total for the deal covering STA-4783, which has demonstrated efficacy in improving median survival rates for melanoma patients in a mid-stage study. Report

> Australia's Living Cell Technologies is garnering headlines with some intriguing responses tracked in a tiny diabetes trial undertaken in Russia. Report

And Finally… Can a pill take grief away? Doctors apparently think so; they're prescribing anti-anxiety meds to the bereaved at record rates--and some patients never stop taking them. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.